title: Centralized drug review processes in Australia, Canada, New Zealand, and the United kingdom.
abstract: Many countries have centralized the clinical and economic assessments necessary for evidence-based drug coverage policy. We analyze such processes in Australia, Canada, New Zealand, and the United Kingdom. These countries apply comparable approaches to the assessment and appraisal of evidence but apply the processes to different types of drugs and use the reviews within different decision-making contexts. Review processes applied to all medicines and clearly tied to coverage decisions appear to influence national drug use. Rigor of process and transparency of data and rationale are believed to be important for maximizing the impact and political acceptability of the processes.
authors.affiliation: University of British Columbia. morgan@chspr.ubc.ca
authors.forename: Steven G
authors.initials: SG
authors.lastname: Morgan
authors.forename: Meghan
authors.initials: M
authors.lastname: McMahon
authors.forename: Craig
authors.initials: C
authors.lastname: Mitton
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Roughead
authors.forename: Ray
authors.initials: R
authors.lastname: Kirk
authors.forename: Panos
authors.initials: P
authors.lastname: Kanavos
authors.forename: Devidas
authors.initials: D
authors.lastname: Menon
mesh_terms: D001315:Australia; D002170:Canada; D003659:Decision Making, Organizational; D017277:Drug Approval / Q000191:economics / Q000458:organization & administration*; D017850:Economics, Pharmaceutical; D019317:Evidence-Based Medicine; D005569:Formularies as Topic; D006077:Government Agencies; D006291:Health Policy; D006801:Humans; D019458:Insurance Coverage; D007356:Insurance, Pharmaceutical Services; D009520:New Zealand; D013997:Time Factors; D006113:United Kingdom; D014481:United States